The AUA/SUFU/AUGS Guideline on Genitourinary Syndrome of Menopause.
Melissa R Kaufman, A Lenore Ackerman, Katherine A Amin...
https://pubmed.ncbi.nlm.nih.gov/40298120/Actively Recruiting
Led by University of Arizona · Updated on 2026-09-21
324
Participants Needed
1
Research Sites
N/A
Total Duration
Researchers are investigating two vaginal treatments, vaginal estrogen and vaginal DHEA, to address vaginal and urinary symptoms related to menopause. These symptoms include vaginal dryness, discomfort, painful intercourse, and urinary issues that can impact quality of life and sexual health. The study aims to better understand how these treatments affect vaginal health and sexual function in peri- and postmenopausal women. Participants will be randomly assigned to use either vaginal estrogen cream or vaginal DHEA suppositories for a set treatment period. Both treatments are applied locally to the vagina, with DHEA converting into estrogen and androgens at the tissue site to help restore moisture and reduce pain. The study involves a double-blind design to fairly compare the effects of these two therapies. During the study, participants will complete questionnaires about their symptoms and sexual health at multiple times. Simple vaginal assessments such as vaginal pH testing and swab collections will be performed at the beginning and end of the study. Researchers will measure genitourinary symptoms and monitor urinary tract infections to evaluate treatment effects. The total study duration includes baseline and a 6-month follow-up period to assess changes and safety.
CONDITIONS
VEDA Study (DHEA vs Estradiol)
I
Iridian (Iris) Jaramillo, M.S.
P
Pamela C Garcia-Filion, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Arizona
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | DHEA (vaginal ovals) | Estradiol 0.01% vaginal cream |
|---|---|---|
| What it is | DHEA (dehydroepiandrosterone) ovals are hormone precursors placed in the vagina, where they get converted locally into estrogen and androgens. This may help restore vaginal lining, improve moisture, and reduce pain for menopausal women. | Estradiol 0.01% vaginal cream is a local estrogen therapy, directly applied for treating thinning, dryness, and irritation of vulvovaginal tissues linked to menopause. |
| Role in trial | DHEA ovals are studied as an active comparator for local symptom relief in peri- or post-menopausal women with vaginal/genitourinary complaints. | Estradiol cream is the other randomized arm, serving as a benchmark for treating genitourinary symptoms in menopause. |
| Primary use | Used for managing symptoms of genitourinary syndrome of menopause, including vaginal dryness, discomfort, and painful intercourse. | Prescribed to treat vaginal dryness, irritation, and pain during intercourse associated with menopausal estrogen decline. |
| How it is given | Administered as vaginal ovals placed directly in the vagina, usually once daily as per study protocol. | Estradiol 0.01% cream is applied intravaginally, typically once a day initially, then potentially less often for maintenance. |
| Evidence status | Multiple randomized trials and meta-analyses support intravaginal DHEA for improvement in vaginal dryness, dyspareunia, and genitourinary syndrome symptoms. | Vaginal estradiol cream is established as a highly effective local therapy for genitourinary menopausal symptoms, with strong evidence from reviews and guidelines. |
| Important risks | Most common side effects include vaginal discharge, irritation, or mild bleeding. Systemic hormone-related events are rarely reported due to local conversion. | Localized irritation or discharge is possible. Absorption is low, but long-term systemic risks in some populations are considered minimal at this dose. |
| Important limitations | Long-term safety data are more limited compared to estradiol. Use may be restricted in women with recent hormone-sensitive cancers or severe vaginal atrophy. | Requires regular application, which may be inconvenient. Caution in estrogen-sensitive cancer survivors, despite low systemic absorption. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants use either vaginal estrogen cream or vaginal DHEA suppositories as assigned randomly to manage menopausal vaginal and urinary symptoms.
Questionnaires and vaginal assessments at start and end of treatment
Duration - Up to 6 months post-treatment
Researchers assess symptom changes and urinary tract infections after treatment to evaluate effectiveness and safety.
Follow-up questionnaires and assessments
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Melissa R Kaufman, A Lenore Ackerman, Katherine A Amin...
https://pubmed.ncbi.nlm.nih.gov/40298120/Wojciech Pięta, Roman Smolarczyk
https://pubmed.ncbi.nlm.nih.gov/33488333/David J Portman, Margery L S Gass, Vulvovaginal Atrophy Terminology Consensus Conference Panel
https://pubmed.ncbi.nlm.nih.gov/25155380/Giulia Misasi, Eleonora Russo, Maria Magdalena Montt Guevara...
https://pubmed.ncbi.nlm.nih.gov/40068355/James A Simon, Irwin Goldstein, Noel N Kim...
https://pubmed.ncbi.nlm.nih.gov/29870471/Irene Porcari, Stefano Uccella, Chiara Casprini...
https://pubmed.ncbi.nlm.nih.gov/40569036/C Bouchard, F Labrie, D F Archer...
https://pubmed.ncbi.nlm.nih.gov/25511551/Elisheva R Danan, Catherine Sowerby, Kristen E Ullman...
https://pubmed.ncbi.nlm.nih.gov/39250810/University of Arizona
Lead Sponsor